|
|||||
|
|
Recent advances in proteomic profiling of pancreatic ductal adenocarcinoma and the road ahead |
|
| Authors: | Hyunsoo Kim Joonho Park Joseph I. Wang |
| Affiliation: | 1. Department of Biomedical Sciences, Seoul National University College of Medicine, Yongon-Dong, Seoul 110-799, Korea;2. Department of Biomedical Engineering, Seoul National University College of Medicine, Yongon-Dong, Seoul 110-799, Korea;3. Institute of Medical and Biological Engineering, Medical Research Center, Seoul National University College of Medicine, Yongon-Dong, Seoul 110-799, Korea;4. Department of Biomedical Engineering, Seoul National University College of Medicine, Yongon-Dong, Seoul 110-799, Korea |
| Abstract: | Introduction: Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers worldwide. However, there remain many unmet clinical needs, from diagnosis to treatment strategies. The inherent complexity of the molecular characteristics of PDAC has made it difficult to meet these challenges, rendering proteomic profiling of PDAC a critical area of research. Area covered: In this review, we present recent advances in mass spectrometry (MS) and its current application in proteomic studies on PDAC. In addition, we discuss future directions for research that can efficiently incorporate current MS-based technologies that address key issues of PDAC proteomics. Expert commentary: Compared with other cancer studies, little progress has been made in PDAC proteomics, perhaps attributed to the difficulty in performing in-depth and large-scale clinical studies on PDAC. However, recent advances in mass spectrometry can advance PDAC proteomics past the fundamental research stage. |
| Keywords: | Pancreatic ductal adenocarcinoma biomarker multiple reaction monitoring quantitative proteomics |